Video Roundtable: APAC Team Talks Key Regional Trends And Topics
Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
From China's new pharma anti-corruption drive to Indian generic firms' strategics challenges, Korean biotechs' global ambitions and Japanese companies' performance in the fiscal first quarter, the APAC region presents a highly varied set of operating environments, challenges and opportunities.
Join the Pink Sheet's on-the-ground team - Brian Yang, Dexter Yan, Anju Ghangurde, Vibha Ravi, Jung Won Shin, Lisa Takagi and myself - in this video overview of recent major biopharma industry topics and trends.
Selected stories covering themes discussed in the roundtable:
(Also see "New China Foreign Investment Policies Include Biopharma Steps" - Pink Sheet, 16 Aug, 2023.)
(Also see "India’s Generics-Only Rx Rule: Not What The Doctor Ordered Or What Pharma Wants?" - Pink Sheet, 24 Aug, 2023.)
(Also see "Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers" - Pink Sheet, 28 Aug, 2023.)
(Also see "China Further Tightens Oversight Of Human Genetic Research" - Pink Sheet, 7 Jun, 2023.)
(Also see "China Drug Makers Brace As Anti-Graft Campaign Impact Surfaces" - Scrip, 24 Aug, 2023.)
(Also see "Draft Biosimilar Red Tape Elimination Act: Pharmacist As Ally, Would Patients Benefit?" - Scrip, 25 Aug, 2023.)
02:00 China pharma corruption drive
08:20 China company earnings
13:20 India company earnings/outlook
17:25 India impact of US Biosimilar Red Tape Elimination Act
22:10 Korean firms eye global market; Korean govt industry support
22:46 Japanese firms' earnings; Japan policy trends
29:45 Wrap up